MARKET

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.00
0.00
0.00%
Closed 16:00 02/24 EST
OPEN
8.00
PREV CLOSE
7.35
HIGH
8.00
LOW
8.00
VOLUME
3
TURNOVER
--
52 WEEK HIGH
9.57
52 WEEK LOW
4.810
MARKET CAP
2.68M
P/E (TTM)
-1.5200
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursd...
GlobeNewswire · 6d ago
Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021 BIO CEO & Investo...
GlobeNewswire · 02/10 12:00
10 Underperforming Stocks Targeted By Short Sellers
Insider Monkey · 02/02 03:05
Cyclacel Pharmaceuticals Announces Key Business Objectives For 2021
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors– – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7
Benzinga · 01/11 12:53
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
- Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors-
GlobeNewswire · 01/11 12:46
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
- Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors-
GlobeNewswire · 01/11 12:46
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
- Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors-
GlobeNewswire · 01/11 12:46
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) Digital 2021
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase(TM) Digit...
GlobeNewswire · 12/30/2020 12:00
More
Forecast
EPSBVPSCFPS
No Data
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYCCP. Analyze the recent business situations of Cyclacel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.05%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
David U'Prichard
President/Chief Executive Officer/Director
Spiro Rombotis
Vice Chairman/Director
Christopher Henney
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul McBarron
Senior Vice President
Mark Kirschbaum
Vice President
Judy Chiao
Director
Brian Schwartz
Director
Karin Walker
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/11/2020
Dividend USD 0.15
01/14/2021
09/10/2020
Dividend USD 0.15
10/15/2020
06/25/2020
Dividend USD 0.15
07/16/2020
03/11/2020
Dividend USD 0.15
04/14/2020
12/10/2019
Dividend USD 0.15
01/16/2020
09/05/2019
Dividend USD 0.15
10/10/2019
05/29/2019
Dividend USD 0.15
07/11/2019
03/07/2019
Dividend USD 0.15
04/12/2019
12/11/2018
Dividend USD 0.15
01/11/2019
09/06/2018
Dividend USD 0.15
10/12/2018
05/31/2018
Dividend USD 0.15
07/12/2018
03/07/2018
Dividend USD 0.15
04/10/2018
12/06/2017
Dividend USD 0.15
01/11/2018
09/07/2017
Dividend USD 0.15
10/12/2017
05/30/2017
Dividend USD 0.15
07/12/2017
03/07/2017
Dividend USD 0.15
04/11/2017
12/07/2016
Dividend USD 0.15
01/13/2017
09/06/2016
Dividend USD 0.15
10/13/2016
05/26/2016
Dividend USD 0.15
07/13/2016
03/29/2016
Dividend USD 0.15
04/14/2016
12/24/2015
Dividend USD 0.15
01/19/2016
10/14/2015
Dividend USD 0.15
10/21/2015
05/22/2015
Dividend USD 0.15
07/15/2015
02/18/2015
Dividend USD 0.15
04/15/2015
12/03/2014
Dividend USD 0.15
12/31/2014
05/22/2014
Dividend USD 0.15
06/27/2014
03/17/2014
Dividend USD 0.15
04/15/2014
12/04/2013
Dividend USD 0.15
01/15/2014
09/10/2013
Dividend USD 0.15
10/17/2013
07/08/2013
Dividend USD 0.15
07/18/2013
04/05/2013
Dividend USD 0.15
04/17/2013
01/11/2013
Dividend USD 0.15
01/17/2013
04/11/2011
Dividend USD 0.15
04/19/2011
01/11/2011
Dividend USD 0.15
01/19/2011
01/07/2009
Dividend USD 0.15
01/14/2009
10/07/2008
Dividend USD 0.15
10/16/2008
07/01/2008
Dividend USD 0.15
07/16/2008
04/08/2008
Dividend USD 0.15
04/16/2008
12/06/2007
Dividend USD 0.15
01/16/2008
09/04/2007
Dividend USD 0.15
10/17/2007
07/06/2007
Dividend USD 0.15
07/18/2007
03/09/2007
Dividend USD 0.15
04/18/2007
01/09/2007
Dividend USD 0.15
01/18/2007
10/06/2006
Dividend USD 0.15
10/19/2006
07/06/2006
Dividend USD 0.15
07/20/2006
04/10/2006
Dividend USD 0.15
04/26/2006
  • All
  • Financials
  • Insiders
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.